May 05, 2020
Acesion Pharma Strengthens Clinical Team With Key Appointments
Feb 28, 2020
HUYA Bioscience International® Announces the Successful Completion of Phase 1 Trial of HBI-3000
Feb 28, 2020
HUYA Bioscience International® Announces the Successful Completion of Phase 1 Trial of HBI-3000
Nov 19, 2019
Atrial Fibrillation Market To Be Majorly Driven By Rising Preference For Catheter Ablation To Treat Cardiac Arrhythmia Till 2020 | Million Insights
Aug 12, 2019
Correvio Announces Brinavess® Spectrum Data to be Presented at the European Society of Cardiology 2019 Congress
Jun 24, 2019
Correvio Resubmits Brinavess (Vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation
Feb 07, 2019
Correvio Announces Presentation Of Brinavess Data At Belgian Society Of Cardiology 2019 Annual Congress
Nov 05, 2018
Acesion Pharma Announces Positive Results for Novel Drug Targeting Atrial Fibrillation
Oct 24, 2018
Cipher Pharmaceuticals Announces Canadian Launch of Brinavess® (vernakalant hydrochloride)
Aug 16, 2018
Correvio Announces EU Survey Data Demonstrating Brinavess Successfully Avoided Hospitalization in 85% of Patients
Aug 30, 2017
New Data Presented at European Society of Cardiology Congress 2017 Highlights Clinical Benefit of BRINAVESS®
Jun 07, 2017
InCarda Therapeutics Announces Positive Clinical Data Supporting Development of Inhaled Flecainide for the Treatment of Symptomatic Acute Events of Paroxysmal Atrial Fibrillation (PAF)